-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Cetylpyridinium Chloride
Category | Hepatitis B Virus (HBV) |
CAS | 123-03-5 |
Description | Cetylpyridinium Chloride is used as an antiseptic in mouthwashes, toothpastes, lozenges, throat sprays, breath sprays, and nasal sprays. |
Product Information
Synonyms | 1-Cetylpyridinium chloride |
Molecular Weight | 339.992 |
Molecular Formula | C21H38ClN |
Canonical SMILES | CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1.[Cl-] |
InChI | InChI=1S/C21H38N.ClH/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19-22-20-17-15-18-21-22;/h15,17-18,20-21H,2-14,16,19H2,1H3;1H/q+1;/p-1 |
InChIKey | YMKDRGPMQRFJGP-UHFFFAOYSA-M |
Melting Point | 83-84°C |
Purity | 0.9944 |
Solubility | Soluble in chloroform (slightly), methanol (slightly). |
Appearance | White to Off-White Solid |
Storage | Room Temperature |
Complexity | 208 |
Exact Mass | 339.2692779 |
In Vitro | Cetylpyridinium chloride interacts with dimeric viral nucleocapsid protein (known as core protein or HBcAg) specifically. Compared with other HBV inhibitors, Cetylpyridinium chloride achieves significantly better reduction of HBV particle number in HepG2.2.15 cell line. Cetylpyridinium chloride inhibits capsid assembly and leads to reduced HBV biogenesis. Cetylpyridinium chloride is a safe antimicrobial agent with broad-spectrum activity for preventing biofilm formation and gingivitis. |
In Vivo | Cetylpyridinium chloride (30 μg/kg; intramuscular injection; daily; for 3 days; male C57BL/6 mice) treatment inhibits HBV replication in mouse hydrodynamic model system. |
PSA | 3.88 |
Target | IC50: 2.5 μM (HBV capsid assembly) |